FDA Approves First Treatment for Eosinophilic Esophagitis

"The U.S. Food and Drug Administration approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in adults and pediatric patients 12 years and older weighing at least 40 kilograms (which is about 88 pounds). Today’s action marks the first FDA approval of a treatment for EoE."

FDA Approves First Treatment for Eosinophilic Esophagitis, a Chronic Immune Disorder | FDA